Avatrombopag

Avatrombopag
Clinical data
Trade names	Doptelet
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	B02BX08 (WHO) ;
Identifiers
	IUPAC name 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid;
CAS Number	570406-98-3 ;
PubChem CID	9852519;
DrugBank	DB11995 ;
ChemSpider	8028230 ;
UNII	3H8GSZ4SQL;
KEGG	D10306;
ChEMBL	ChEMBL2103883 ;
CompTox Dashboard (EPA)	DTXSID30205667 ;
Chemical and physical data
Formula	C29H34Cl2N6O3S2
Molar mass	649.65 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl;
	InChI InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) ; Key:OFZJKCQENFPZBH-UHFFFAOYSA-N;
(what is this?)

Avatrombopag is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adult patients who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in 2018.[1]

References

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure